toripalimab + JS212

Toripalimab + JS212 is an investigational combination therapy being developed for the treatment of various advanced solid tumors, including lung cancer, triple-negative breast cancer, renal cell carcinoma, prostate cancer, urothelial carcinoma, and melanoma. The combination consists of toripalimab, a recombinant humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), and JS212, a first-in-class recombinant humanized bispecific antibody-drug conjugate (ADC) targeting both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) conjugated to a topoisomerase I inhibitor payload (exatecan). By combining immune checkpoint inhibition via toripalimab with dual-receptor-targeted cytotoxic delivery via JS212, the regimen aims to enhance antitumor efficacy, induce immunogenic cell death, and overcome resistance mechanisms associated with single-target therapies in advanced malignancies.